Griniūte Rasa, Bumblyte Inga Arūne
Clinic of Hematology, Clinic of Nephrology, Kaunas University of Medicine, Lithuania.
Medicina (Kaunas). 2003;39 Suppl 1:41-7.
Presenting clinical and laboratory features, prognostic implications and survival in 124 multiple myeloma patients were reviewed in a retrospective study based on hospital records. The median age was 65 years. Out of all patients, 2.42% were younger than 40 years and 62.9% were 60 years and older. The main presenting clinical features were bone pain (70.16%), fatigue (31.45%), recurrent infections (9.68%) and weight loss (0.3%). Renal failure was present in 35.48% of patients. The higher means of ionised calcium, uric acid, erythrocyte sedimentation rate, M protein were correlated with the higher mean of serum creatinine. The acturial survival of myeloma patients without renal failure at 1 and 2 years was 95.08% and 89.23% respectively, while acturial survival of myeloma patients with renal failure at 1 and 2 years was 82.5% and 73.35% respectively (p<0.01). One-year survival in myeloma patients maintained on chronic hemodialysis was 68.75% while it is reported as 90.91% for myeloma patients not on dialysis (p<0.006).
基于医院记录进行的一项回顾性研究,对124例多发性骨髓瘤患者的临床和实验室特征、预后影响及生存率进行了分析。患者的中位年龄为65岁。所有患者中,2.42%年龄小于40岁,62.9%年龄在60岁及以上。主要临床表现为骨痛(70.16%)、疲劳(31.45%)、反复感染(9.68%)和体重减轻(0.3%)。35.48%的患者存在肾衰竭。离子钙、尿酸、红细胞沉降率、M蛋白的均值较高与血清肌酐均值较高相关。无肾衰竭的骨髓瘤患者1年和2年的实际生存率分别为95.08%和89.23%,而有肾衰竭的骨髓瘤患者1年和2年的实际生存率分别为82.5%和73.35%(p<0.01)。维持慢性血液透析的骨髓瘤患者1年生存率为68.75%,而未进行透析的骨髓瘤患者报告的1年生存率为90.91%(p<0.006)。